Literature DB >> 31748838

Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes.

Laleh Razavi-Nematollahi1, Faramarz Ismail-Beigi2.   

Abstract

PURPOSE OF REVIEW: Treatment of patients with type 2 diabetes mellitus is focused on preventing the occurrence and delaying the development of macro- and micro-vascular complications. Glycemic control can help prevent these complications, but there is concern about the adverse effects of glycemia-lowering medications. A rational approach is to balance the desired low risk of adverse events against the unwanted higher risk of major complications resulting from suboptimal glucose control. RECENT
FINDINGS: Using the above approach, approved glucose-lowering agents have favorable benefit-to-risk profiles for use in most patients with type 2 diabetes. We first briefly review the mechanism of actions and benefits of the different commonly used classes of glycemia-lowering medications and then discuss adverse effects and safety concern associated with their use. Our overall assessment is that if used appropriately, the different classes of glycemia-lowering medications offer beneficial outcomes with relatively modest and, in some instances, preventable adverse events.

Entities:  

Keywords:  Congestive heart failure; Euglycemic diabetic acidosis (euDKA); Genital infections; Lactic acidosis; Necrotizing fasciitis; Severe hypoglycemia

Mesh:

Substances:

Year:  2019        PMID: 31748838     DOI: 10.1007/s11892-019-1266-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  76 in total

Review 1.  PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth.

Authors:  E D Rosen; B M Spiegelman
Journal:  J Biol Chem       Date:  2001-07-17       Impact factor: 5.157

2.  Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.

Authors:  William M Steinberg; John B Buse; Marie Louise Muus Ghorbani; David D Ørsted; Michael A Nauck
Journal:  Diabetes Care       Date:  2017-05-05       Impact factor: 19.112

3.  Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.

Authors:  A Tura; J I Bagger; E Ferrannini; J J Holst; F K Knop; T Vilsbøll; A Mari
Journal:  Nutr Metab Cardiovasc Dis       Date:  2017-10-13       Impact factor: 4.222

4.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

Authors:  Yoon K Loke; Sonal Singh; Curt D Furberg
Journal:  CMAJ       Date:  2008-12-10       Impact factor: 8.262

5.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.

Authors:  Erland Erdmann; John A Dormandy; Bernard Charbonnel; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene
Journal:  J Am Coll Cardiol       Date:  2007-04-16       Impact factor: 24.094

6.  Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Authors:  Kathleen M Dungan; Santiago Tofé Povedano; Thomas Forst; José G González González; Charles Atisso; Whitney Sealls; Jessie L Fahrbach
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

Review 7.  SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.

Authors:  Kelly R Burke; Christine A Schumacher; Spencer E Harpe
Journal:  Pharmacotherapy       Date:  2017-01-16       Impact factor: 4.705

8.  Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.

Authors:  Nelson B Watts; John P Bilezikian; Keith Usiskin; Robert Edwards; Mehul Desai; Gordon Law; Gary Meininger
Journal:  J Clin Endocrinol Metab       Date:  2015-11-18       Impact factor: 5.958

9.  The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.

Authors:  Denise E Bonds; Michael E Miller; Richard M Bergenstal; John B Buse; Robert P Byington; Jeff A Cutler; R James Dudl; Faramarz Ismail-Beigi; Angela R Kimel; Byron Hoogwerf; Karen R Horowitz; Peter J Savage; Elizabeth R Seaquist; Debra L Simmons; William I Sivitz; Joann M Speril-Hillen; Mary Ellen Sweeney
Journal:  BMJ       Date:  2010-01-08

10.  Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

Authors:  Louise E Robinson; Tim A Holt; Karen Rees; Harpal S Randeva; Joseph P O'Hare
Journal:  BMJ Open       Date:  2013-01-24       Impact factor: 2.692

View more
  4 in total

1.  Evaluation of Anti-Diabetic and Anti-Hyperlipidemic Activities of Hydro-Alcoholic Crude Extract of the Shoot Tips of Crinum abyssinicum Hochst. ex A. Rich (Amaryllidaceae) in Mice.

Authors:  Bantayehu Addis Tegegne; Abebe Basazn Mekuria; Eshetie Melese Birru
Journal:  J Exp Pharmacol       Date:  2022-02-01

2.  Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Hoda Taheri; Mojtaba Malek; Faramarz Ismail-Beigi; Farhad Zamani; Masoudreza Sohrabi; Mohammad Reza Babaei; Mohammad E Khamseh
Journal:  Adv Ther       Date:  2020-09-25       Impact factor: 3.845

3.  Ultrasound-Assisted Extraction Optimization of α-Glucosidase Inhibitors from Ceratophyllum demersum L. and Identification of Phytochemical Profiling by HPLC-QTOF-MS/MS.

Authors:  Zhen Li; Zongcai Tu; Hui Wang; Lu Zhang
Journal:  Molecules       Date:  2020-10-01       Impact factor: 4.411

Review 4.  Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.

Authors:  Young Sup Woo; Hyun Kook Lim; Sheng-Min Wang; Won-Myong Bahk
Journal:  Int J Mol Sci       Date:  2020-09-22       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.